Soft Tissue Sarcoma Cancer Stem Cells: An Overview

Katia C Genadry, Silvia Pietrobono, Rossella Rota, Corinne M Linardic

Research output: Contribution to journalReview article

Abstract

Soft tissue sarcomas (STSs) are an uncommon group of solid tumors that can arise throughout the human lifespan. Despite their commonality as non-bony cancers that develop from mesenchymal cell precursors, they are heterogeneous in their genetic profiles, histology, and clinical features. This has made it difficult to identify a single target or therapy specific to STSs. And while there is no one cell of origin ascribed to all STSs, the cancer stem cell (CSC) principle-that a subpopulation of tumor cells possesses stem cell-like properties underlying tumor initiation, therapeutic resistance, disease recurrence, and metastasis-predicts that ultimately it should be possible to identify a feature common to all STSs that could function as a therapeutic Achilles' heel. Here we review the published evidence for CSCs in each of the most common STSs, then focus on the methods used to study CSCs, the developmental signaling pathways usurped by CSCs, and the epigenetic alterations critical for CSC identity that may be useful for further study of STS biology. We conclude with discussion of some challenges to the field and future directions.

Original languageEnglish
Pages (from-to)475
Number of pages17
JournalFrontiers in Oncology
Volume8
DOIs
Publication statusPublished - 2018

Fingerprint

Neoplastic Stem Cells
Sarcoma
Neoplasms
Disease Resistance
Epigenomics
Histology
Stem Cells
Therapeutics
Neoplasm Metastasis
Recurrence

Cite this

Soft Tissue Sarcoma Cancer Stem Cells : An Overview. / Genadry, Katia C; Pietrobono, Silvia; Rota, Rossella; Linardic, Corinne M.

In: Frontiers in Oncology, Vol. 8, 2018, p. 475.

Research output: Contribution to journalReview article

Genadry, Katia C ; Pietrobono, Silvia ; Rota, Rossella ; Linardic, Corinne M. / Soft Tissue Sarcoma Cancer Stem Cells : An Overview. In: Frontiers in Oncology. 2018 ; Vol. 8. pp. 475.
@article{ccf5015d8d6443a1853b08c8c3c998c3,
title = "Soft Tissue Sarcoma Cancer Stem Cells: An Overview",
abstract = "Soft tissue sarcomas (STSs) are an uncommon group of solid tumors that can arise throughout the human lifespan. Despite their commonality as non-bony cancers that develop from mesenchymal cell precursors, they are heterogeneous in their genetic profiles, histology, and clinical features. This has made it difficult to identify a single target or therapy specific to STSs. And while there is no one cell of origin ascribed to all STSs, the cancer stem cell (CSC) principle-that a subpopulation of tumor cells possesses stem cell-like properties underlying tumor initiation, therapeutic resistance, disease recurrence, and metastasis-predicts that ultimately it should be possible to identify a feature common to all STSs that could function as a therapeutic Achilles' heel. Here we review the published evidence for CSCs in each of the most common STSs, then focus on the methods used to study CSCs, the developmental signaling pathways usurped by CSCs, and the epigenetic alterations critical for CSC identity that may be useful for further study of STS biology. We conclude with discussion of some challenges to the field and future directions.",
author = "Genadry, {Katia C} and Silvia Pietrobono and Rossella Rota and Linardic, {Corinne M}",
year = "2018",
doi = "10.3389/fonc.2018.00475",
language = "English",
volume = "8",
pages = "475",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Soft Tissue Sarcoma Cancer Stem Cells

T2 - An Overview

AU - Genadry, Katia C

AU - Pietrobono, Silvia

AU - Rota, Rossella

AU - Linardic, Corinne M

PY - 2018

Y1 - 2018

N2 - Soft tissue sarcomas (STSs) are an uncommon group of solid tumors that can arise throughout the human lifespan. Despite their commonality as non-bony cancers that develop from mesenchymal cell precursors, they are heterogeneous in their genetic profiles, histology, and clinical features. This has made it difficult to identify a single target or therapy specific to STSs. And while there is no one cell of origin ascribed to all STSs, the cancer stem cell (CSC) principle-that a subpopulation of tumor cells possesses stem cell-like properties underlying tumor initiation, therapeutic resistance, disease recurrence, and metastasis-predicts that ultimately it should be possible to identify a feature common to all STSs that could function as a therapeutic Achilles' heel. Here we review the published evidence for CSCs in each of the most common STSs, then focus on the methods used to study CSCs, the developmental signaling pathways usurped by CSCs, and the epigenetic alterations critical for CSC identity that may be useful for further study of STS biology. We conclude with discussion of some challenges to the field and future directions.

AB - Soft tissue sarcomas (STSs) are an uncommon group of solid tumors that can arise throughout the human lifespan. Despite their commonality as non-bony cancers that develop from mesenchymal cell precursors, they are heterogeneous in their genetic profiles, histology, and clinical features. This has made it difficult to identify a single target or therapy specific to STSs. And while there is no one cell of origin ascribed to all STSs, the cancer stem cell (CSC) principle-that a subpopulation of tumor cells possesses stem cell-like properties underlying tumor initiation, therapeutic resistance, disease recurrence, and metastasis-predicts that ultimately it should be possible to identify a feature common to all STSs that could function as a therapeutic Achilles' heel. Here we review the published evidence for CSCs in each of the most common STSs, then focus on the methods used to study CSCs, the developmental signaling pathways usurped by CSCs, and the epigenetic alterations critical for CSC identity that may be useful for further study of STS biology. We conclude with discussion of some challenges to the field and future directions.

U2 - 10.3389/fonc.2018.00475

DO - 10.3389/fonc.2018.00475

M3 - Review article

C2 - 30416982

VL - 8

SP - 475

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

ER -